Mitomycin Medac (Mitomycin)

• Mitomycin is an antineoplastic antibiotic used primarily in the management of bladder cancer.
• Non‑muscle invasive bladder cancer: reduces recurrence and progression after transurethral resection.
• Superficial bladder carcinoma: provides intravesical chemotherapy to eradicate residual tumor cells.
• Carcinoma in situ of bladder: used as adjunctive intravesical therapy to achieve local disease control.

• Mitomycin acts as an alkylating agent that forms covalent cross‑links between DNA strands, preventing DNA replication and transcription. The resulting DNA damage triggers apoptosis and cell death, particularly in rapidly dividing urothelial cancer cells, while sparing most normal tissues when administered intravesically.

Mitomycin may cause a range of adverse reactions, from mild local irritation to serious systemic toxicity.

Common Side Effects

• Bladder irritation or burning sensation during or after instillation.
• Dysuria and increased urinary frequency.
• Hematuria or mild blood in urine.
• Low‑grade fever or chills.
• Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects

• Bone marrow suppression leading to anemia, neutropenia, or thrombocytopenia.
• Renal toxicity manifesting as elevated creatinine or reduced clearance.
• Severe allergic reactions, including anaphylaxis.
• Pulmonary fibrosis or interstitial lung disease.
• Life‑threatening infection secondary to immunosuppression.

• Mitomycin requires careful monitoring and specific safety measures before and during treatment.
• Renal function: assess baseline creatinine and adjust use in renal impairment.
• Hematologic status: obtain complete blood count and monitor for bone‑marrow suppression.
• Urinary tract infection: treat any active infection before intravesical administration.
• Pregnancy: contraindicated because fetal risk is unknown; avoid use in pregnant patients.
• Concurrent systemic chemotherapy: avoid overlapping exposure to reduce cumulative toxicity.
• Store at below 25°C: keep in original container, protect from light and moisture.

Mitomycin can interact with other drugs, altering its safety or efficacy.

Major Interactions (Avoid)

• Concurrent systemic chemotherapy: increased systemic toxicity.
• Pelvic radiation therapy: heightened bladder irritation and ulceration.
• Nephrotoxic agents (e.g., cisplatin, aminoglycosides): risk of renal impairment.

Moderate Interactions (Monitor Closely)

• Anticoagulants: potential for increased bleeding.
• Immunosuppressants: heightened infection risk.
• NSAIDs: may exacerbate renal side effects.